CAMBRIDGE, Mass.--(BUSINESS WIRE)--Third paragraph should read: Prior to joining F-Prime, Mr. Grass spent 15 years, most recently as senior vice president of business and corporate development, at BioMarin, a California-based biotechnology company developing and commercializing treatments for rare genetic diseases. In this role, Mr. Grass was part of the senior executive team that raised more than $2B in capital, developed a global commercial and manufacturing infrastructure, launched five products and completed many product in-licensings, acquisitions and divestitures. (Instead of Prior to joining F-Prime, Mr. Grass spent 15 years as the director of business development and finance at BioMarin, a California-based biotechnology company developing and commercializing treatments for rare genetic diseases. In this role, Mr. Grass was part of the senior executive team that raised more than $2B in capital, developed a global commercial and manufacturing infrastructure, launched five products and completed a number of product in-licensings, acquisitions and divestitures.)
The corrected release reads:
F-PRIME CAPITAL ANNOUNCES JOSHUA GRASS AS NEW ENTREPRENEUR-IN-RESIDENCE
F-Prime Capital, a global venture capital firm focused on investments in healthcare and technology, today announced that Joshua Grass has joined the firm as entrepreneur-in-residence. Mr. Grass will primarily focus on advancing life sciences company-creation activities at F-Prime.
“We are excited to welcome Josh to the firm and believe he will be an important asset to F-Prime,” said Stephen Knight, managing partner of F-Prime Capital. “Josh’s experience growing BioMarin, a leading biotech company, will be invaluable as we continue our work of building and investing in biotechnology companies. His efforts have helped advance multiple medicines, having a direct and immediate impact on patients. We look forward to working with him to build more great companies.”
Prior to joining F-Prime, Mr. Grass spent 15 years, most recently as senior vice president of business and corporate development, at BioMarin, a California-based biotechnology company developing and commercializing treatments for rare genetic diseases. In this role, Mr. Grass was part of the senior executive team that raised more than $2B in capital, developed a global commercial and manufacturing infrastructure, launched five products and completed many in-licensings, acquisitions and divestitures.
“F-Prime has a strong track record of creating and investing in companies that develop innovative medicines for serious diseases, including FoldRx, Ironwood, Orchard, Dimension, and Ultragenyx,” said Mr. Grass. “I look forward to lending my insights and experience as we work together to create new companies doing important work.”
About F-Prime Capital Partners
F-Prime Capital is a global venture capital firm investing in life sciences, healthcare and technology. Since 1969, F-Prime has worked closely with entrepreneurs and academics to create innovative solutions to some of the world’s most significant challenges in healthcare and technology.
